Contact a Rep at EISAI ENGAGE

This site is intended for U.S. health
care professionals only.

LENVIMA® (lenvatinib) capsules 10 mg and 4 mg logo
Select an Indication
RAI-refractory DTC 1st-Line treatment of aRCC 2nd-Line treatment of aRCC 1st-Line treatment of uHCC Advanced EC
LENVIMA® for adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer

LENVIMA dosing and administration

Once a day. Every day. With or without food1

LENVIMA dosing for RAI-R differentiated thyroid cancer is once a day, every day, with or without food graphic. LENVIMA dosing for RAI-R differentiated thyroid cancer is once a day, every day, with or without food graphic mobile

Recommended LENVIMA dose: 24 mg (two 10-mg capsules and one 4-mg capsule).1

    Preparation of suspension:

  • Place the required number of capsules, up to a maximum of 5, in a small container (approximately 20 mL capacity) or syringe (20 mL). Do not break or crush capsules
  • Add 3 mL of liquid to the container or syringe. Wait 10 minutes for the capsule shell (outer surface) to disintegrate, then stir or shake the mixture for 3 minutes until capsules are fully disintegrated and administer the entire contents
  • Next, add an additional 2 mL of liquid to the container or syringe using a second syringe or dropper, swirl or shake and administer. Repeat this step at least once and until there is no visible residue to ensure all of the medication is taken
  • If 6 capsules are required for a dose, follow these instructions using 3 capsules at a time

If LENVIMA suspension is not used at the time of preparation, LENVIMA suspension may be stored in a refrigerator at 36°F to 46°F (2°C to 8°C) for a maximum of 24 hours in a covered container. If not administered within 24 hours, the suspension should be discarded.

Note: Compatibility has been confirmed for polypropylene syringes and for feeding tubes of at least 5 French diameter (polyvinyl chloride or polyurethane tube) and at least 6 French diameter (silicone tube).

Dose modifications for renal or hepatic impairment

Recommended dose of LENVIMA for severe renal or hepatic impairment1

LENVIMA dosage can be adjusted for severe renal impairment or severe hepatic impairment. LENVIMA dosage can be adjusted for severe renal impairment or severe hepatic impairment mobile.

No dose adjustment is recommended in patients with mild or moderate renal or hepatic impairment.*

LENVIMA has not been studied in patients with end-stage renal disease.

CrCl=creatinine clearance.

  1. *Mild renal impairment is defined as CrCl 60-89 mL/min and moderate renal impairment is defined as CrCl 30-59 mL/min. Mild and moderate hepatic impairment is defined as Child-Pugh A and Child-Pugh B, respectively.
  2. aAs calculated by the Cockcroft-Gault equation.

LENVIMA capsules are supplied in cartons of 6 blister cards. Each carton contains a 30-day supply of LENVIMA capsules1

  • Continue LENVIMA until disease progression or until unacceptable toxicity
  • LENVIMA should be taken at the same time each day. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped, and the next dose should be taken at the usual time of administration
  • LENVIMA is available as 10-mg and 4-mg capsules
LENVIMA capsules are supplied in cartons of 6 blister cards, with a 24-mg daily dose taken in 10 mg and 4 mg capsules. LENVIMA capsules are supplied in cartons of 6 blister cards, with a 24-mg daily dose taken in 10 mg and 4 mg capsules mobile
Eisai Engage logo

Eisai Engage

Connect to HCP services at Eisai Engage to request materials for your practice, contact a sales representative, and more.

Visit Eisai Engage now
Safety AR Management